Business Description
Xeris Biopharma is a Chicago-based pharmaceutical company focused on bringing treatments to market for people living with long-term hormonal and neurological conditions. Its current lineup includes three approved medicines: Gvoke for severe low blood sugar, Keveyis for a rare muscle disorder, and Recorlev for Cushing's syndrome, a condition caused by excess cortisol. The company is also running a late-stage clinical trial for XP-8121, a once-weekly injection designed to treat an underactive thyroid. Founded in 2005, Xeris continues to grow its portfolio of targeted therapies for patients with complex, chronic conditions.
